BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 12615728)

  • 1. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.
    Kang JY; Dolled-Filhart M; Ocal IT; Singh B; Lin CY; Dickson RB; Rimm DL; Camp RL
    Cancer Res; 2003 Mar; 63(5):1101-5. PubMed ID: 12615728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma.
    Kataoka H; Hamasuna R; Itoh H; Kitamura N; Koono M
    Cancer Res; 2000 Nov; 60(21):6148-59. PubMed ID: 11085539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
    Betsunoh H; Mukai S; Akiyama Y; Fukushima T; Minamiguchi N; Hasui Y; Osada Y; Kataoka H
    Cancer Sci; 2007 Apr; 98(4):491-8. PubMed ID: 17309599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hepatocyte growth factor regulatory factors in human breast cancer.
    Parr C; Watkins G; Mansel RE; Jiang WG
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):202-11. PubMed ID: 14734471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.
    Oberst MD; Johnson MD; Dickson RB; Lin CY; Singh B; Stewart M; Williams A; al-Nafussi A; Smyth JF; Gabra H; Sellar GC
    Clin Cancer Res; 2002 Apr; 8(4):1101-7. PubMed ID: 11948120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
    Shia S; Stamos J; Kirchhofer D; Fan B; Wu J; Corpuz RT; Santell L; Lazarus RA; Eigenbrot C
    J Mol Biol; 2005 Mar; 346(5):1335-49. PubMed ID: 15713485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
    Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
    Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ST14 gene variant and decreased matriptase protein expression predict poor breast cancer survival.
    Kauppinen JM; Kosma VM; Soini Y; Sironen R; Nissinen M; Nykopp TK; Kärjä V; Eskelinen M; Kataja V; Mannermaa A
    Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2133-42. PubMed ID: 20716618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pericellular activation of hepatocyte growth factor/scatter factor (HGF/SF) in colorectal carcinomas: roles of HGF activator (HGFA) and HGFA inhibitor type 1 (HAI-1).
    Kataoka H; Itoh H; Hamasuna R; Meng JY; Koono M
    Hum Cell; 2001 Mar; 14(1):83-93. PubMed ID: 11436357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas.
    Hecht M; Papoutsi M; Tran HD; Wilting J; Schweigerer L
    Cancer Res; 2004 Sep; 64(17):6109-18. PubMed ID: 15342394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
    Parr C; Jiang WG
    Int J Cancer; 2006 Sep; 119(5):1176-83. PubMed ID: 16557597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocyte growth factor activator inhibitor type‑1 in cancer: advances and perspectives (Review).
    Zheng Q; Wu H; Cao J; Ye J
    Mol Med Rep; 2014 Dec; 10(6):2779-85. PubMed ID: 25310042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
    Kirchhofer D; Peek M; Lipari MT; Billeci K; Fan B; Moran P
    FEBS Lett; 2005 Mar; 579(9):1945-50. PubMed ID: 15792801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The green tea catechins, (-)-Epigallocatechin-3-gallate (EGCG) and (-)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells.
    Bigelow RL; Cardelli JA
    Oncogene; 2006 Mar; 25(13):1922-30. PubMed ID: 16449979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma.
    Yamauchi M; Kataoka H; Itoh H; Seguchi T; Hasui Y; Osada Y
    J Urol; 2004 Feb; 171(2 Pt 1):890-6. PubMed ID: 14713848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor.
    Hashimoto T; Kato M; Shimomura T; Kitamura N
    FEBS J; 2010 Dec; 277(23):4888-900. PubMed ID: 20977675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis.
    Ruco LP; Stoppacciaro A; Ballarini F; Prat M; Scarpino S
    J Pathol; 2001 May; 194(1):4-8. PubMed ID: 11329134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
    Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
    Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
    Saleem M; Adhami VM; Zhong W; Longley BJ; Lin CY; Dickson RB; Reagan-Shaw S; Jarrard DF; Mukhtar H
    Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):217-27. PubMed ID: 16492908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular genetic analysis of the hepatocyte growth factor/MET signaling pathway in pediatric medulloblastoma.
    Onvani S; Terakawa Y; Smith C; Northcott P; Taylor M; Rutka J
    Genes Chromosomes Cancer; 2012 Jul; 51(7):675-88. PubMed ID: 22447520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.